CHICAGO, June 13 /PRNewswire/ -- The Emergency Nurses Association (ENA)
today announced that PDL BioPharma(R) had been named a strategic partner
for 2007. As a strategic partner, PDL BioPharma(R) will be the exclusive
sponsor for the ENA State Leaders December Orientation and the Emergency
Nurses Week, October 7-13, 2007.
"We are very pleased to announce this partnership with PDL
BioPharma(R)," said Donna Mason, RN, MS, CEN, ENA President. "By partnering
with ENA, PDL BioPharma(R) gets a unique opportunity to show their support
of the life saving work of emergency nurses across the county."
Through this partnership, PDL BioPharma(R) will help finance ongoing
educational opportunities, professional networking activities as well as
events honoring nurses during emergency nurses week.
"As a leader in the discovery, development and manufacturing of
innovative therapies for serious or life-threatening illnesses, PDL
BioPharma(R) has great respect for the work done by nurses in emergency
departments every day," said Jaisim Shah, senior vice president, marketing
and business affairs, PDL BioPharma Inc.
"Like our ground breaking drugs for short-term hypertension treatment
and acute myocardial infarction, these healthcare professionals are saving
lives everyday. Through this partnership, we hope to raise the visibility
of emergency nurses while showing our appreciation for everything that they
In the United States and Canada, PDL BioPharma(R) markets several
commercial biopharmaceutical products for the hospital setting --
Cardene(R) I.V. (http://www.pdlbiopharma.com/index.cfm?navid=32) for the
short-term treatment of hypertension, Retavase(R)
(http://www.pdlbiopharma.com/index.cfm?navid=35) for acute myocardial
infarction and IV Busulfex(R)
(http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning
http://www.pdlbiopharma.com/index.cfm?navid=142) for conditioning prior to
a bone marrow transplant in association with chronic myelogenous leukemia.
About the Emergency Nurses Association
The Emergency Nurses Association (ENA) is the only professional nursing
association dedicated to defining the future of emergency nursing and
emergency care through advocacy, expertise, innovation, and leadership.
Founded in 1970, ENA serves as the voice of more than 32,000 members and
their patients through research, publications, professional development,
injury prevention, and patient education. Additional information is
available at ENA's Web site, at http://www.ena.org.
About PDL BioPharma(R)
PDL BioPharma(R), Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life-threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of products in the
United States and Canada. A pioneer of antibody humanization technology,
PDL promotes this technology through licensing agreements and clinical
development of its own diverse pipeline of investigational compounds. PDL's
research platform centers on the discovery and development of antibodies to
treat cancer and autoimmune diseases. For more information, please visit
SOURCE Emergency Nurses Association